Skip to content
CheckOrphan
  • Home
  • About Us
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
    • Research
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • About Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu

Subscribe for Free Newsletter

Email *

Type *

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. Clinical Trial
  4. /
  5. Phase II Trial of...

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

May 27, 2020checkorphan
Learn more about:
Neurofibromatosis type 2
Related Clinical Trial
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Recruitment Information

Administrative Informations

Related News

  • US Doctors Give Zimbabwe Man New Face
  • PTC Therapeutics Receives $2.6 Million in Government Grants
More News

Related Treatment

  • Bortezomib
More Treatment

Related

  • Bortezomib
  • The Neuro Foundation
  • The Children’s Tumor Foundation
  • The British Columbia Neurofibromatosis Foundation
  • Neurofibromatosis Network
  • Neurofibromatosis type 2
  • US Doctors Give Zimbabwe Man New Face
  • PTC Therapeutics Receives $2.6 Million in Government Grants
More
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2024 CheckOrphan.
    Developed by: Gonza.io logo Developed by: WebOptimalSolutions Powered by: Cloudscale logo